BPC-157

Mechanism

BPC-157 is a synthetic pentadecapeptide (15 amino acids) derived from a sequence in human gastric juice. Its precise molecular mechanism is not fully elucidated, but research suggests it:

• Upregulates growth hormone receptor expression in tendon fibroblasts
• Promotes fibroblast proliferation and collagen synthesis
• Enhances angiogenesis via VEGFR2 activation
• Modulates the nitric oxide system
• Demonstrates anti-inflammatory effects via multiple pathways

These mechanisms have been characterised primarily in animal and in vitro models.

Evidence base

Tendon, Ligament, and Muscle Healing

Animal studies demonstrate accelerated healing of tendon, ligament, and muscle tissue with BPC-157. Proposed mechanisms include upregulation of growth hormone receptor expression and enhanced collagen synthesis (Sikiric et al., 2018).

Gastrointestinal Healing

Originally studied for gastroprotective effects. Animal studies show protection against gastric ulcers and NSAID-induced damage. Systematic review of preclinical evidence confirms consistent effects (Sikiric et al., 2018).

Neurological and Wound Healing

Emerging preclinical research suggests nerve regeneration, reduced oxidative stress, and accelerated wound healing (Park et al., 2020).

Evidence Quality: Limited

Extensive and consistent preclinical (animal) data, but a near-complete absence of published human clinical trials. No RCTs in humans as of 2025.

FDA Compounding Risk Alert (2025)

The FDA issued a compounding risk alert in early 2025 listing BPC-157 among unapproved drug products that do not meet safety standards for compounding. This signals enforcement risk and growing regulatory scrutiny of unapproved peptides globally (FDA, 2025).

Protocols

In research and community discussions, BPC-157 is commonly discussed in the following contexts:

• Dose range: 250–500 mcg per administration (discussed in research contexts; no human dosing trials to validate)
• Frequency: Once to twice daily
• Cycle length: 2–4 weeks, followed by time off
• Route: Subcutaneous injection near the site of injury; oral administration explored for GI indications
• Administration: Subcutaneous injection with insulin syringe

These protocols are derived from community discussion and extrapolation from animal studies. No human pharmacokinetic data exists to validate dosing. Research use only.

UK legal status

BPC-157 is not a licensed medicine in the UK. Not available on NHS or private prescription. Legal to purchase and possess for bona fide research purposes. Supplying for human consumption without MHRA authorisation breaches UK medicines regulations (Human Medicines Regulations 2012).

The FDA's 2025 compounding risk alert on BPC-157 reflects growing international regulatory scrutiny. The MHRA has not issued equivalent guidance specifically naming BPC-157, but the regulatory environment is tightening globally. UK position: research use permissible; human therapeutic use not authorised.

Vendor notes

BPC-157 is widely available through UK research peptide vendors. Researchers should always request a Certificate of Analysis (COA) and verify third-party purity testing before purchasing. See vetted vendor listings for suppliers meeting Peptide Data verification standards.